Legal & General Group Plc Grows Stock Holdings in Stryker Corporation $SYK

Legal & General Group Plc raised its stake in Stryker Corporation (NYSE:SYK) by 2.7% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,366,107 shares of the medical technology company’s stock after buying an additional 62,817 shares during the period. Legal & General Group Plc’s holdings in Stryker were worth $831,616,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. VanderPol Investments L.L.C. boosted its position in Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after buying an additional 28 shares during the period. Lantz Financial LLC boosted its position in Stryker by 5.0% in the 3rd quarter. Lantz Financial LLC now owns 608 shares of the medical technology company’s stock valued at $225,000 after buying an additional 29 shares during the period. Stonebridge Capital Advisors LLC boosted its position in Stryker by 0.4% in the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock valued at $2,661,000 after buying an additional 29 shares during the period. Tcfg Wealth Management LLC boosted its position in Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after buying an additional 29 shares during the period. Finally, Mechanics Financial Corp boosted its position in Stryker by 1.2% in the 4th quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock valued at $864,000 after buying an additional 30 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Price Performance

Shares of SYK opened at $316.39 on Monday. The company has a 50 day moving average price of $325.22 and a 200-day moving average price of $349.76. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The stock has a market capitalization of $121.29 billion, a PE ratio of 36.62, a PEG ratio of 1.99 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the previous year, the company posted $2.84 EPS. Stryker’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Wells Fargo & Company lowered their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Leerink Partners started coverage on shares of Stryker in a research report on Monday, April 13th. They issued an “outperform” rating and a $410.00 price target for the company. Canaccord Genuity Group lowered their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Finally, Needham & Company LLC lowered their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $395.48.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. The trade was a 28.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.60% of the stock is currently owned by company insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.